1. CHEMICAL IDENTIFICATION

Product Name: DOCP (desoxycorticosterone pivalate) injectable suspension  
CAS No: 808-48-0

Trade Name(s): Percorten®-V

Active Ingredient (%): Desoxycorticosterone pivalate (2.5%)

Chemical Name: 21-Hydroxy-4-pregnene-3,20-dione-trimethylacetate

Chemical Class: Mineralocorticoid Hormone

EPA Signal Word: Not Applicable

2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Materials</th>
<th>OSHA PEL</th>
<th>ACGIH TLV</th>
<th>NTP/IARC/OSHA Carcinogen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desoxycorticosterone Pivalate</td>
<td>None</td>
<td>0.01 mg/m³</td>
<td>No</td>
</tr>
</tbody>
</table>

* Novartis Pharmaceutical Division PIEL

3. HAZARDS IDENTIFICATION

Notes to Physician:
See First Aid #4. Finished Pharmaceutical Product – Refer to Veterinary Pharmaceuticals & Biologicals Desk Reference

Symptoms of Acute Exposure:
The potential for exposure is reduced in this form. Repeated skin contact may cause a sensitization (allergic) reaction in sensitive individuals.

Hazardous Decomposition Products:
None known

4. FIRST AID MEASURES

Note: Finished Pharmaceutical Product – Refer to Veterinary Pharmaceuticals & Biologicals Desk Reference

If human exposure is suspected, immediately contact a physician, the nearest hospital, or nearest Poison Control Center. Tell the person contacted the complete product name, chemical class, and type and amount of exposure. Describe any symptoms and follow the advice given.

**Finished pharmaceutical product. No hazard is expected from normal clinical use.**

Ingestion: No hazard is expected from normal clinical use.
Eye Contact: No hazard is expected from normal clinical use.
Skin Contact: No hazard is expected from normal clinical use.
Inhalation: No hazard is expected from normal clinical use.

Product Name: Percorten®-V
Novartis Animal Health US Inc.
Notes to Physician:
There is no specific antidote if this product is ingested. If a large amount has been ingested and emesis is inadequate, lavage stomach. Five g/kg of activated carbon suspension (50 g/400 ml water) can be given to absorb remaining product. Treat symptomatically together with measures to correct fluid and electrolyte imbalance. In case of hypokalemia, digitalis should be used only with caution.*

Based on the acute oral LD$_{50}$ in rats, ingestion of 60 mls or more may be fatal to an adult human.*

Medical Conditions Likely to be Aggravated by Exposure:
Hypertension, cardiac disease or hypersensitivity to desoxycorticosterone. Persons with allergic history or pre-existing dermatitis should use extra care in handling this product. No hazard is expected from normal clinical use.*

*Based on the technical material

5. FIRE FIGHTING MEASURES

Flash Point (Test Method) Not Applicable
Flammable Limits (% in Air) Not Applicable
Autoignition Temperature Not Available
Flammability Not Applicable

Unusual Fire, Explosion and Reactivity Hazards:
None Known

In Case of Fire:
Under normal conditions of use this material does not present a significant fire or explosion hazard.

6. ACCIDENTAL RELEASE MEASURES

In Case of Spill or Leak:
Cover with an absorbent material, such as pet litter, sweep up and place in an approved chemical waste container. Wash the area with water containing a strong detergent, absorb with absorbent material, sweep up and place in chemical container. Flush the area with water to remove any residue. Avoid contamination of sewers and waterways.

7. HANDLING AND STORAGE

Store the vials at room temperature between 59-86° F (15-30° C). Protect from light and protect from freezing temperatures. Shelf life is two years.
8. EXPOSURE CONTROL/PERSONAL PROTECTION

Respiratory Protection: Not required under normal conditions of therapeutic administration and use.
Eye Protection: Not required under normal conditions of therapeutic administration and use.
Skin Protection: Not required under normal conditions of therapeutic administration and use.
Ventilation: Not required under normal conditions of therapeutic administration and use.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: White aqueous suspension
Odor: Not available
Melting Point: Not applicable
Boiling Point: Not applicable
Specific Gravity/Density: Not available
pH: 5 – 7.0
Evaporation Rate: Not available
Solubility in Water: Not available
Vapor Pressure: Not available

10. STABILITY AND REACTIVITY

Reactivity: 
Stability: Stable
Conditions to Avoid: None Known
Hazardous Decomposition Products: None Known

11. TOXICOLOGICAL INFORMATION

Acute Toxicity/Irritation Studies
Ingestion: Moderately toxic Oral LD$_{50}$ (Mouse) =1,000 mg/kg body weight.*
Dermal: Not available
Inhalation: Not available
Eye Contact: Not available
Skin Contact: Not available
Skin Sensitization: Sensitizing
Carcinogenicity: Non-carcinogen
Chronic/Subchronic Toxicity Studies: Not available
Toxicity of Other Components: None known
*Data based on the technical material.

12. ECOLOGICAL INFORMATION

Summary of Effects: Not available
Eco-Acute Toxicity: Not available

Product Name: Percorten$^\text{R}$-V
Novartis Animal Health US Inc.
13. DISPOSAL CONSIDERATION

Disposal: While not a hazardous waste, material should be disposed of in an environmentally sound manner. All wastes must be disposed of in accordance with local, state and federal laws and regulations. (Contact local or state environmental agency for specific rules.)

14. TRANSPORT INFORMATION

DOT Classification: Not Applicable; No Label or Placard Required
B/L Freight Classification: Pharmaceutical Chemical, N.O.S.

15. REGULATORY INFORMATION

SARA Title III Classification:
Section 311/312: Acute Health Hazard
Proposition 65: Not determined
CERCLA Reportable Quantity (RQ): None
RCRA Classification: Not applicable
TSCA Status: Exempt from TSCA

16. OTHER INFORMATION

NFPA Hazard Ratings:

<table>
<thead>
<tr>
<th>Health</th>
<th>1</th>
<th>0</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flammability</td>
<td>0</td>
<td></td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reactivity</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Questions concerning the safe handling of the product should be referred to:
Novartis Animal Health US, Inc.
1-800-637-0281

Issued Date: 03/22/94
Revised Date: 10/31/00

The information and recommendations contained herein are based upon data believed to be correct. However, no guarantee or warranty of any kind, expressed or implied, is made with respect to the information contained herein.